Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100656 | 0.92 | MTNR1A (0.49) | MTNR1AMTNR1BHDAC1HDAC6 | |
| SCHEMBL6050076 | 0.86 | MTNR1A (0.49) | MTNR1AMTNR1BHDAC1HDAC6 | |
| SCHEMBL6667447 | 0.85 | AKR1C3 (0.50) | MTNR1AMTNR1BHDAC1HDAC6 | |
| SCHEMBL10202967 | 0.83 | MTNR1A (0.54) | MTNR1AMTNR1B | |
| SCHEMBL28820181 | 0.82 | MTNR1A (0.57) | MTNR1AMTNR1BHDAC1HDAC6SIGMAR1 | |
| SCHEMBL28020307 | 0.82 | MTNR1A (0.57) | MTNR1AMTNR1BHDAC1HDAC6SIGMAR1 | |
| SCHEMBL14286887 | 0.82 | CYSLTR2 (0.58) | MTNR1AMTNR1BHDAC1HDAC6CHRM2 | |
| SCHEMBL11419614 | 0.82 | MTNR1A (0.46) | MTNR1AMTNR1BCHRM3 | |
| SCHEMBL10596068 | 0.82 | AKR1C3 (0.49) | MTNR1AMTNR1B | |
| SCHEMBL1858307 | 0.82 | MTNR1A (0.53) | MTNR1AMTNR1BHDAC1HDAC6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7321044-B2 | Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-22 | — | — | US | disclosed |
| EP-1436254-A1 | SYNTHESIS OF OXYGEN-SUBSTITUTED BENZOCYCLOHEPTENES, USED AS VALUABLE INTERMEDIATE PRODUCTS FOR PRODUCING TISSUE-SELECTIVE OESTROGENS | Schering Aktiengesellschaft (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-20030162974-A1 | Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens | SCHERING AG (DE) | 2003-08-28 | — | — | US | disclosed |
| WO-2003033461-A1 | SYNTHESIS OF OXYGEN-SUBSTITUTED BENZOCYCLOHEPTENES, USED AS VALUABLE INTERMEDIATE PRODUCTS FOR PRODUCING TISSUE-SELECTIVE OESTROGENS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162974-A1 | Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens | CYP19A1, HSD17B11, SULT1E1 | MTNR1A 757/4885MTNR1B 987/4885HDAC1 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.